Results 201 to 210 of about 2,987,883 (293)

Non‐Metastatic Squamous Cell Carcinoma of the Oropharynx: Primary Surgery or (Chemo)radiotherapy?

open access: yesHead &Neck, EarlyView.
ABSTRACT Background In patients with locally advanced, non‐metastatic oropharyngeal squamous cell carcinoma (OPSCC), surgery‐based and nonsurgical treatment approaches have not been adequately compared in randomized Phase III clinical trials. Current clinical guidelines recommend various surgical and nonsurgical strategies across disease stages for ...
Primož Strojan   +12 more
wiley   +1 more source

Stereotactic Body Radiotherapy (SBRT) of Previously Unirradiated Mucosal Head and Neck Squamous Cell Carcinoma (SCC)

open access: yesHead &Neck, EarlyView.
ABSTRACT Purpose To evaluate the efficacy and safety of stereotactic body radiation therapy (SBRT) in previously untreated primary mucosal head and neck cancer (HNC) patients unfit for conventional radiation therapy. Materials and Methods Retrospective analysis of previously unirradiated primary SCC mucosal HNC patients treated with SBRT from 2011 to ...
Mohammed Aldohan   +10 more
wiley   +1 more source

A Discharge Summary Prompt Reduces Postoperative Radiotherapy Delay in Head and Neck Cancer Patients

open access: yesHead &Neck, EarlyView.
ABSTRACT Background Delays in postoperative radiotherapy (PORT) beyond 6 weeks are associated with worse outcomes in head and neck cancer (HNC). This study evaluated whether a discharge summary prompt could reduce PORT delay. Methods A retrospective review of patients from 2018 to 2023 was used as a pre‐intervention baseline.
Andreja Radevic   +10 more
wiley   +1 more source

Neoadjuvant Atezolizumab and Chemotherapy for Non‐Squamous Non‐Small Cell Lung Cancer: Efficacy and Safety Results of an Open‐Label, Single‐Arm, Phase II Trial

open access: yesInternational Journal of Cancer, EarlyView.
Surgery plus chemotherapy is a well‐established treatment protocol for resectable, locally advanced non‐small cell lung cancer (NSCLC). Nonetheless, survival gains remain limited, emphasizing the need for more effective treatments. Here, the authors evaluated a novel approach using a neoadjuvant immunotherapy‐chemotherapy regimen consisting of ...
Benedikt Niedermaier   +19 more
wiley   +1 more source

Indirect Comparison of Neoadjuvant Treatment Strategies for Muscle‐Invasive Bladder Cancer: ddMVAC and Perioperative Durvalumab‐Gemcitabine‐Cisplatin Versus Gemcitabine‐Cisplatin: A Systematic Review and Network Meta‐Analysis of Randomised Controlled Trials

open access: yesInternational Journal of Cancer, EarlyView.
Optimizing neoadjuvant therapy for muscle‐invasive bladder cancer patients who are eligible for cisplatin remains difficult, owing particularly to high toxicity and recurrence rates. This meta‐analysis compared dose‐dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) against durvalumab plus gemcitabine‐cisplatin (D‐GC) and GC alone ...
Maurin Helen Mangold   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy